Skip to main content
Log in

Improvement of Metabolic Syndrome Following Intragastric Balloon: 1 Year Follow-up Analysis

  • Clinical Report
  • Published:
Obesity Surgery Aims and scope Submit manuscript

Abstract

Objective

This study aimed to assess the impact of intragastric balloon (IGB)-induced body weight loss on metabolic syndrome in obese patients and evaluate what happens during 1-year follow-up.

Methods

To this end, data were collected on 143 obese patients (body mass index (BMI) 36.2 ± 5.7 kg/m²) who underwent IGB insertion between January 2000 and December 2005. Outcomes were recorded at BioEnterics Intragastric Balloon removal time (t 0) and at 6-month (t 6) and 12-month (t 12) follow-up.

Results

Significant BMI, excess body weight loss percentage, and body weight loss percentage (BWL%) were observed at t 0 (29.6 ± 4.6 kg/m²; 29.3 ± 4.8%; 14.1 ± 5.7%), followed by partial weight regain at t 12 (32.4 ± 4.3 kg/m²; 26.1 ± 4.9%; 11.2 ± 4.6%). Incidence of metabolic syndrome dropped from 34.8% (pre-IGB value) to 14.5% (t 0) and 11.6% (t 12). Likewise, type 2 diabetes mellitus (DM), hypertriglyceridemia, hypercholesterolemia, and blood hypertension (BH) incidence decreased from 32.6%, 37.7%, 33.4%, and 44.9% (pre-IGB values) to 20.9%, 14.5%, 16.7%, and 30.4% at t 0 and 21.3%, 17.4%, 18.9%, and 34.8% at t 12. HbA1c blood concentration shifted from an initial value of 7.5 ± 2.1% to 5.7 ± 1.9% (t 0), 5.6 ± 0.7% (t 6), and 5.5 ± 0.9% (t 12). Patients suffering from DM or BH stopped or diminished relative drug consumption at t 12. Negligible modifications were reported as regards HDL cholesterol and hyperuricemia.

Conclusion

Weight regain is commonly observed during long-term follow-up after IGB removal. Nevertheless, the maintenance of at least 10% of the BWL%, as reported at 1-year follow-up, is associated with an improvement in metabolic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Loffredo A, Cappuccio M, De Luca M, et al. Three years experience with the new intragastric balloon, and a preoperative test for success with restrictive surgery. Obes Surg. 2001;11:330–3.

    Article  CAS  Google Scholar 

  2. Roman S, Napoleon B, Mion F, et al. Intragastric balloon for “non-morbid” obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14:539–44.

    Article  Google Scholar 

  3. Doldi SB, Micheletto G, Perrini MN, et al. Treatment of morbid obesity with intragastric balloon in association with diet. Obes Surg. 2002;12:583–92.

    Article  CAS  Google Scholar 

  4. De Waele B, Reynaert H, Urbain D, et al. Intragastric balloons for preoperative weight reduction. Obes Surg. 2000;10:58–60.

    Article  Google Scholar 

  5. Wahlen CH, Bastens B, Herve J, et al. The BioEnterics Intragastric Balloon (BIB): how to use it. Obes Surg. 2001;11:524–7.

    Article  CAS  Google Scholar 

  6. Spyropoulos C, Katsakoulis E, Mead N, et al. Intragastric balloon for high-risk super-obese patients: a prospective analysis of efficacy. Surg Obes Relat Dis. 2007;3:78–83.

    Article  Google Scholar 

  7. Sallet JA, Marchesini JB, Pavia DS, et al. Brazilian multi center study of intragastric balloon. Obes Surg. 2004;14:991–8.

    Article  Google Scholar 

  8. Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18:841–6.

    Article  Google Scholar 

  9. Mittempergher F, Di Betta E, Pata G, et al. The obstructive sleep apnea in bariatric surgery. Ann Ital Chir. 2008;79:165–70.

    PubMed  Google Scholar 

  10. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.

    Article  CAS  Google Scholar 

  11. Strazzullo P, Barbato A, Siani A, et al. Diagnostic criteria for metabolic syndrome: a comparative analysis in an unselected sample of adult male population. Metabolism. 2008;57:355–61.

    Article  CAS  Google Scholar 

  12. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359:2105–20.

    Article  CAS  Google Scholar 

  13. Ammar KA, Redfield MM, Mahoney DW, et al. Central obesity: association with left ventricular dysfunction and mortality in the community. Am Heart J. 2008;156:975–81.

    Article  Google Scholar 

  14. Shimabukuro M. Cardiac adiposity and global cardiometabolic risk: new concept and clinical intervention. Circ J. 2008;73:27–34.

    Article  Google Scholar 

  15. Artham SM, Lavie CJ, Patel HM. Impact of obesity on the risk of heart failure and its prognosis. J Cardiometab Syndr. 2008;3:155–61.

    Article  Google Scholar 

  16. Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107:1755–67.

    Article  Google Scholar 

  17. Avenell A, Brown TJ, McGee MA, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004;17:293–316.

    Article  CAS  Google Scholar 

  18. Curioni CC, Lourenço PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond). 2005;29:1168–74.

    Article  CAS  Google Scholar 

  19. Herve J, Wahlen H, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70.

    Article  CAS  Google Scholar 

  20. Angrisani L, Lorenzo M, Borrelli V, et al. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg. 2006;16:1135–7.

    Article  Google Scholar 

  21. Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon free follow-up. Gastrointest Endosc. 2005;61:19–27.

    Article  Google Scholar 

  22. Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric Balloon: the Italian Experience with 2.515 patients. Obes Surg. 2005;15:1161–4.

    Article  CAS  Google Scholar 

  23. Mui WL, Ng EK, Tsung BY et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2008; (in press).

  24. Ricci G, Bersani G, Rossi A, et al. Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients. Obes Surg. 2008;18:1438–42.

    Article  Google Scholar 

  25. Deitel M. How much weight loss is sufficient to overcome major co-morbidities? Obes Surg. 2001;11:659.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nicola Crea.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crea, N., Pata, G., Della Casa, D. et al. Improvement of Metabolic Syndrome Following Intragastric Balloon: 1 Year Follow-up Analysis. OBES SURG 19, 1084–1088 (2009). https://doi.org/10.1007/s11695-009-9879-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11695-009-9879-6

Keywords

Navigation